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Deregulated Myc triggers a variety of intrinsic tumor suppressor programs that serve to restrain Myc’s onco-
genic potential. Since Myc activity is also required for normal cell proliferation, activation of intrinsic tumor
suppression must be triggered only when Myc signaling is oncogenic. However, how cells discriminate
between normal and oncogenic Myc is unknown. Here we show that distinct threshold levels of Myc govern
its output in vivo: low levels of deregulated Myc are competent to drive ectopic proliferation of somatic cells
and oncogenesis, but activation of the apoptotic and ARF/p53 intrinsic tumor surveillance pathways requires
Myc overexpression. The requirement to keep activated oncogenes at a low level to avoid engaging tumor
suppression is likely an important selective pressure governing the early stages of tumor microevolution.INTRODUCTION
The Myc oncoprotein is a pleiotropic transcription factor of the
basic helix-loop-helix-leucine zipper family with the essential
role of engaging and coordinating expression of the diverse
genes necessary for efficient and orderly proliferation of somatic
cells. In normal cells, both mRNA and protein expression of
c-Myc are low and continuously dependent on mitogen signaling
(Liu and Levens, 2006; Rabbitts et al., 1985; Ramsay et al., 1984).
In most human cancers, by contrast, Myc expression is deregu-
lated and/or elevated. Sometimes this is due to alterations in the
myc gene itself that disrupt its normal regulation (e.g., chromo-
somal translocation, retrovirus integration, or gene amplifica-
tion), increase myc mRNA or Myc protein stability, or abrogate
Myc autorepression (reviewed by Nesbit et al., 1999; Popescu
and Zimonjic, 2002; Spencer and Groudine, 1991). In mostCtumors, however, the c-myc gene appears normal, and its
elevated and persistent activity appears to be due to its relent-
less induction by upstream oncoproteins, such as oncogenic
kinases, Ras, or the Wnt/b-catenin pathway.
The extent to which Myc deregulation versus Myc overexpres-
sion contributes to Myc oncogenic activity is unclear. Increasing
Myc levels often correlate with the more advanced and aggres-
sive variants of tumors, suggesting that overexpression plays
some part in Myc-driven oncogenesis. Moreover, since overex-
pression drives novel interactions between Myc and low-affinity
promoter elements, some have suggested that Myc’s oncogenic
actions arise from precocious recruitment of novel genes
(Fernandez et al., 2003). On the other hand, deregulation of
Myc without overexpression is sufficient to obviate the depen-
dency of normal cell proliferation on mitogens and to block the
response of cycling cells to antiproliferative cues. This is mostSIGNIFICANCE
Cancers are prevented by the activation of intrinsic tumor suppressor programs that either fix the damage in cells or ensure
that the damaged cells cannot propagate. Cancers can only arise once these tumor suppressor pathways are abrogated.
Importantly, activation of such tumor suppressor pathways must be restricted only to oncogenic, not normal, growth
signals. Using an in vivo model of Myc-induced tumorigenesis in which Myc function is deregulated without concomitant
overexpression, we show that tumor surveillance programs are triggered specifically by Myc overexpression, not
deregulation. Nonetheless, low-level deregulated Myc remains potently oncogenic. These observations identify a mecha-
nism by which the tumor suppressor defense mechanisms can be circumvented, with implications for our understanding
of early-stage neoplasia.ancer Cell 14, 447–457, December 9, 2008 ª2008 Elsevier Inc. 447
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normal Myc target genes.
It is now generally accepted that spontaneous tumorigenesis
is largely suppressed by the obligate coupling of proliferation
to antioncogenic programs such as senescence and apoptosis
(Evan and Littlewood, 1998; Lowe et al., 2004). Myc is a prototyp-
ical example of this phenomenon. Oncogenically activated Myc
is a potent inducer of cell proliferation but also engages the ARF/
p53 tumor suppressor pathway (Eischen et al., 1999; Kamijo
et al., 1998; Schmitt et al., 1999; Zindy et al., 1998) and apoptosis
(Askew et al., 1991; Evan et al., 1992), both tumor suppressor
programs that antagonize cell expansion and restrict Myc’s
oncogenic potential. However, since Myc mediates the prolifer-
ation of normal cells, it is clear that activation of ARF/p53
and apoptosis must be restricted to situations wherein Myc is
Figure 1. Characteristics of MycERT2 Expression in R26lsl-MER
Mouse Embryonic Fibroblasts
(A) Rosa26-driven MycERT2 expression in R26lsl-MER mouse embryonic fibro-
blasts (MEFs) is Cre recombinase dependent and transgene dose dependent.
R26lsl-MER/WT MEFs were infected with retrovirus driving control vector () or
Cre recombinase (+) and selected with puromycin for 3 days. Western blotting
of whole-cell lysates with anti-human ERa antibody reveals expression of the
predicted 92 kDa MycERT2 fusion protein. Asterisk denotes a nonspecific
band.
(B) Simultaneous comparison of levels of endogenous Myc and MycERT2 in
wild-type (WT), R26MER/WT, and R26MER/MER MEFs. MEFs were isolated from
embryos of each genotype and cultured in complete growth medium/10%
FBS. Equal numbers of cell equivalents from each lysate were western blotted
with SC42 anti-Myc antibody, detecting an epitope common to endogenous
Myc and MycERT2. Extracts from serum-deprived WT MEFs and from WT
MEFs 2 hr after addition of fresh medium were probed alongside, together
with an equivalent number of HeLa cells, which overexpress c-Myc
(30,000 molecules per cell), for comparison (Moore et al., 1987).
(C) Dose-dependent expression of MycERT2 mRNA driven from the Rosa26
locus. qPCR quantitation (mean + SEM) of MycERT2 mRNA isolated from
WT, R26MER/WT, and R26MER/MER MEFs is shown normalized to GUS (n = 3).448 Cancer Cell 14, 447–457, December 9, 2008 ª2008 Elsevier Inconcogenic. How cells distinguish between Myc that is activated
by mitogenic signals and Myc that is oncogenically activated is
unknown, although candidates include the abnormal persis-
tence of oncogenic Myc, its activation outside the normal
context of other mitogenic signals, and its overexpression.
To address these issues, we have developed aMyc transgenic
mouse in which latent expression of the reversibly switchable
variant of Myc, MycERT2, is driven by the constitutive and ubiq-
uitously active Rosa26 promoter. Overt MycERT2 expression is
then triggered in any target tissue by the hit-and-run action of
Cre recombinase. Due to the relative weakness of the Rosa26
promoter, the level of MycER expressed in tissues of such
animals is very low and close to the physiological level of Myc
following normal mitogen stimulation. We have used this model
to define the oncogenic properties of Myc in vivo when deregu-
lated but not significantly overexpressed. Our studies indicate
that the level at which Myc is expressed plays an unforeseen
and critical role in determining its oncogenic potential.
RESULTS
Generation of R26-lsl-MERT2 and R26-MERT2 Mice
The switchable, 4-hydroxytamoxifen (4-OHT)-dependent variant
of Myc was generated by fusing Myc to the modified hormone-
binding domain of the modified estrogen receptor ERT2 (Indra
et al., 1999). To direct conditional expression of MycERT2 to
target tissues, the cDNA was inserted downstream of the ubiqui-
tously active Rosa26 locus, preceded by a strong translational
termination sequence flanked by loxP recombination sites.
Murine embryonic stem cell clones transfected with the resulting
targeting vector were screened by Southern blotting to identify
single insertions into the Rosa26 locus (see Figure S1 available
online). Germline transmission of the R26-lsl-MycERT2 allele by
chimeric mice was verified by PCR amplification across the
Myc-ERT2 sequence junction. We refer to the resulting line of
mice as R26-lsl-MERT2.
To verify that MycERT2 expression is dependent upon excision
of the translational termination element, we expressed Cre
recombinase in R26-lsl-MERT2-derived mouse embryonic fibro-
blasts (MEFs). Immunoblotting with anti-human ERa antibody
demonstrated expression of the predicted 92 kDa MycERT2
fusion protein only in MEFs expressing Cre (Figure 1A). To di-
rectly compare in somatic cells and tissues the levels ofMycERT2
expression driven from one or two copies of the Rosa26
promoter with those of endogenous Myc, R26-lsl-MERT2 mice
were crossed with the germline deletor strain ZP3-Cre (Lewan-
doski et al., 1997). Rosa26-driven MycERT2 is expressed in all
somatic cells of such crosses, which we henceforth refer to
as R26MER mice. Relative levels of endogenous Myc and
ectopic MycERT2 proteins in log-phase, serum-deprived, and
serum-stimulated wild-type (WT) MEFs and in heterozygous
R26MER/WT and homozygous R26MER/MER MEFs were then
compared by immunoblotting cell extracts with SC42 anti-Myc
antibody, which recognizes an epitope common to Myc and
MycERT2. MycERT2, absent from WT MEFs, was expressed in
homozygous R26MER/MER cells at approximately twice the level
present in heterozygous R26MER/WT cells (Figure 1B). This was
confirmed at the mRNA level by real-time quantitative PCR
(qPCR) (Figure 1C). The steady-state level of MycERT2 in.
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in R26MER/MER MEFs a little higher than, that of endogenous Myc
in logarithmically growing WT MEFs, and far below the 30,000
Myc molecules per cell present in HeLa cells (Moore et al., 1987).
MycERT2 protein half-life was short (15–20 min) (Figure S2A), es-
sentially identical to that of endogenous Myc (Flinn et al., 1998;
Ramsay et al., 1984). Unlike endogenous Myc, however, R26-
driven MycERT2 expression was unaffected by serum status
(Figure S2B). Above 10,000 total Myc molecules per cell,
Myc autoregulates, suppressing expression from its endoge-
nous promoter (Penn et al., 1990). To ascertain whether
MycERT2, when activated, is expressed at a level sufficient to
suppress endogenous Myc, we repeated the analysis in Fig-
ure 1B using MEFs treated continuously with 4-OHT to activate
MycERT2. We observed negligible downregulation of endoge-
nous Myc upon activation of MycERT2 in either R26MER/WT or
R26MER/MER MEFs (Figure S2C), consistent with the very low
levels of MycERT2 present in R26MER MEFs.
We used qPCR with selective primers both to quantitate the
relative levels of endogenous myc versus MycERT2 mRNA in
tissues of tamoxifen-treated and untreated R26MER/MER mice
Figure 2. Dose-Dependent Induction of Proliferation
by Rosa26-Driven MycERT2 In Vivo
(A) qPCR analysis of MycERT2 mRNA levels (mean + SEM) in
selected organs from untreated adult R26lsl-MER/lsl-MER (white
bars), R26MER/WT (gray bars), and R26MER/MER (black bars)
mice, normalized to GUS (n = 3).
(B) Representative images of two-color immunofluorescent
detection of BrdU/IdU incorporation, indicating instances of
S phase progression in mice treated daily with tamoxifen
for 6 days. Yellow-orange indicates BrdU incorporation
(S phase on day 3); green indicates IdU incorporation (S phase
on day 6).
(C) Quantification (mean + SEM) of BrdU incorporation in
tissues of control, R26MER/WT, and R26MER/MER mice at day 6.
and to assess whether endogenous Myc expres-
sion is suppressed by R26-driven MycERT2
in vivo. As expected, levels of endogenous Myc
were extremely low in nonproliferating tissues. In
spleen, where cell proliferation is substantial,
MycERT2 mRNA levels were comparable to those
of endogenous myc. We observed no significant
suppression of endogenous Myc upon activation
of MycERT2 in any tissue aside from colonic epithe-
lium (Figure S3).
Deregulated Expression of Low-Level Myc
Induces Ectopic Proliferation in Multiple
Adult Tissues
The relative contributions to oncogenesis made
by Myc deregulation versus Myc overexpression
remain unclear. The low level of deregulated
MycERT2 expression in R26MER tissues therefore
provided a unique opportunity to ascertain the
impact of Myc deregulation, without overt over-
expression, in adult mouse tissues. To confirm
MycERT2 expression in tissues, RNA was extracted
from multiple organs from adult (2-month-old) homozygous
R26-lsl-MERT2, heterozygous R26MER/WT, and homozygous
R26MER/MER mice, andMycERT2 transcript levels were quantified
by qPCR.MycERT2mRNA was essentially undetectable in any or-
gans of R26-lsl-MERT2 mice but exhibited gene-dose-dependent
expression in all tested organs of R26MER animals (Figure 2A).
To acutely activate MycERT2 in all tissues, tamoxifen was
systemically administered daily for 6 days to adult R26WT/WT,
R26MER/WT, and R26MER/MER mice. Proliferation in tissues was
assessed by systemic administration of bromodeoxyuridine
(BrdU) at day 3 followed by iododeoxyuridine (IdU) at day 6 to
capture initial and delayed S phases (Burns and Kuan, 2005).
BrdU and IdU incorporation in most tissues of tamoxifen-treated
R26MER/WT animals (with the exception of colonic epithelium; see
below) was indistinguishable from that in R26WT/WT; by contrast,
we saw a marked increase in incorporation of both BrdU and IdU
in multiple tissues of homozygous R26MER/MER animals (Fig-
ure 2B), including exocrine pancreas, endocrine pancreas,
kidney, liver, and lung. Of note, no proliferation was observed
in skeletal or cardiac muscle, or in brain aside from the epithelial
choroid plexus (Table S1). These data demonstrate thatCancer Cell 14, 447–457, December 9, 2008 ª2008 Elsevier Inc. 449
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tained proliferation in a significant subset of tissues. However,
MycERT2-induced proliferation was only evident in homozygous
R26MER/MER tissues (Figure 2C), indicating that a critical
minimum threshold level of Myc is needed to drive proliferation
in ‘‘permissive’’ tissues and that this threshold is straddled by
the levels of MycERT2 expression in hetero- and homozygous
Rosa26-MERT2 mice. Ipso facto, we conclude that the ectopic
Myc activity in tissues of homozygous R26MER/MER mice is close
to the minimum required to drive ectopic proliferation.
Different Threshold Levels of Myc Trigger Myc-Induced
Proliferation versus Induction of Apoptosis and ARF
Myc-induced apoptosis is a key intrinsic tumor suppressor
mechanism that limits Myc’s oncogenic potential. However,
the factors that determine whether proliferation or cell death is
the predominant outcome of Myc activation remain unclear. To
ascertain whether activation of low-level MycERT2 induces apo-
ptosis in tissues in vivo, Myc was activated systemically in adult
R26MER/MER mice for 0, 3, or 6 days, and tissue sections from
multiple organs were then probed with Ki-67-specific antibody
to identify cells in cycle and by TUNEL to identify apoptotic cells.
As with our BrdU/IdU incorporation data, proliferation was
robustly induced by 3 days of MycERT2 activation in the same
proliferation-permissive organs as above, remaining elevated
at 6 days in pancreatic islets, kidney, and lung (Figure 3A and
Figure 3. Widespread Myc-Induced Ectopic Prolifera-
tion Occurs without Apoptosis in R26MER/MER Mice
(A) Organs from adult R26MER/MER mice treated for 3 days
with tamoxifen (tam) (n = 7) or oil carrier (n = 6), assessed for
proliferation (Ki-67 staining) and apoptosis (TUNEL assay).
Activation of MycERT2 drives abundant ectopic cell-cycle
entry in multiple tissues (exocrine and endocrine pancreas,
kidney, liver, lung, and colon are presented). However, with
the exception of colon (inset), no tissues exhibited concomi-
tant Myc-induced apoptosis. Scale bars = 25 mm.
(B) Quantification (mean + SEM) of Ki-67 staining in colon
sections from tamoxifen-treated R26WT/WT (n = 4), R26MER/WT
(n = 6), and R26MER/MER mice (n = 3) and from R26MER/MER
mice treated with carrier (n = 3). t test analysis indicates that
the increase in proliferation from R26WT/WT to R26MER/WT is
significant (*p = 0.001), as is the increase from R26MER/WT to
R26MER/MER (**p = 0.004).
(C) Quantification (mean + SEM) of TUNEL-positive cells in
sections of colonic epithelium from the mice in (B).
Figure S4; summarized in Table S1). However, we
observed no Myc-induced apoptosis in any tissues
(again, with the exception of colonic epithelium;
see below). We conclude that quasiphysiological
levels of deregulated Myc are sufficient to drive
proliferation in most permissive tissues without
engaging concomitant apoptosis.
As mentioned, colonic epithelium of R26MER/MER
mice was a notable exception to the above pattern:
here, Myc activation induced abundant apoptosis.
Provocatively, out of all R26MER tissues tested,
colonic epithelium exhibited the highest level of
MycERT2 expression (Figure 2A). Indeed, even the
single allele of MycERT2 in heterozygous R26MER/WT mice drove
Myc expression sufficient to trigger proliferation in colonic
epithelium upon activation (p = 0.001; Figure 3B). In colonic
epithelium of homozygous R26MER/MER animals (Figure 3B),
Myc-induced proliferation was even more marked, although
accompanied by apoptosis (Figure 3C). Together, these obser-
vations intimated that induction of apoptosis in vivo might
require a higher level of Myc than proliferation.
Like apoptosis, induction of p19ARF by oncogenic Myc is a crit-
ical restraint to Myc oncogenesis that, by activating p53 through
inhibition of Mdm2 (Kamijo et al., 1998; Weber et al., 1999; Zindy
et al., 1998), can both drive apoptosis (Hermeking and Eick,
1994; Wagner et al., 1994; Zindy et al., 1998) and suppress
proliferation (Finch et al., 2006). p19ARF may also exert p53-inde-
pendent tumor-suppressive functions (Lowe and Sherr, 2003), in
part mediated by direct binding and functional inactivation of
Myc (Datta et al., 2004; Qi et al., 2004). To ascertain whether
the low yet mitogenic level of deregulated Myc in tissues of
R26MER/MER mice is sufficient to induce ARF expression, we
quantified p19ARF mRNA and protein expression following
MycERT2 activation (Figure 4A). Notwithstanding some variability
in measured basal levels of ARF mRNA between tissues and
individual isolates, we saw no measurable induction by Myc of
ARF mRNA or protein in any tissue except, once again, colonic
epithelium. Because it has recently been suggested that even
extremely low levels of p19ARF may exert tumor-suppressive450 Cancer Cell 14, 447–457, December 9, 2008 ª2008 Elsevier Inc.
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cally that the Myc phenotypes we observed in vivo were
p19ARF independent by crossing the R26MER/MER mice into the
ARF/ background. ARF status had no impact on the extent,
kinetics, or duration of Myc-induced proliferation in most
R26MER/MER mouse tissues (Figures 4B and 4C). Together, these
data show that the low level of deregulated Myc expressed in
most proliferation-permissive tissues of R26MER/MER mice, while
adequate to induce widespread proliferation, is insufficient to
engage the p19ARF/p53 tumor suppressor pathway.
R26MER/MER colonic epithelium was, again, an exception to the
above: Myc activation induced a >2-fold induction of ARFmRNA
(Figure 4A; p = 0.004) in colon, and induction of p19ARF was con-
firmed by immunoblotting of colonocyte lysates prepared from
fresh tissue (data not shown). Furthermore, Myc-induced colo-
nocyte proliferation was significantly enhanced in the ARF/
background (Figure 4D). As with apoptosis, this is consistent
with the notion that induction of p19ARF requires higher levels
of Myc than proliferation.
To ascertain directly whether the thresholds for Myc-induced
proliferation versus tumor suppression (induction of apoptosis
and ARF) are set at different levels of Myc expression in vivo,
we used the pIns-MycERTAM b cell mouse model, in which the
powerful rat insulin promoter drives high-level expression of
4-OHT-dependent MycER in pancreatic b cells (Figure S5A).
Figure 4. Activation of MycERT2 in Most Tissues of
R26MER/MER Mice Does Not Induce the p19ARF Tumor
Suppressor
(A) qPCR analysis for expression of ARF mRNA in organs
from adult R26MER/MER mice treated for 3 days with tamoxifen
(n = 7) or oil carrier (n = 7), normalized to GUS. No ARF was
induced by MycERT2 activation in any tissue tested, except
for colonic epithelium, where it was statistically significant
(*p = 0.004).
(B) Representative two-color immunofluorescence images of
tissues from R26MER/MER;ARF+/+ (n = 7) and R26MER/MER;
ARF/ (n = 4) mice injected daily with tamoxifen for 6 days.
Mice were systemically pulsed with BrdU on day 2 and IdU
on day 6, as in Figure 2, to identify cells in S phase on day 2
(yellow-orange) and day 6 (green).
(C) Quantification (mean + SEM) of BrdU incorporation on day
6. Note that the ARF+/+ data are the same as those presented
in Figure 2C.
(D) Quantification (mean + SEM) of Ki-67 staining of colon
sections from the indicated mice treated for 3 days with
tamoxifen. Data for ARF+/+ samples are the same as those
presented in Figure 3B. R26WT/WT;ARF/(n = 3); R26MER/MER;
ARF/ (n = 2).
We previously showed that activation of Myc in
this model efficiently triggers b cell proliferation
but that this is rapidly curtailed by concomitant ac-
tivation of both apoptosis and induction of nucleo-
lar p19ARF (Figures S5A, S5B, and S6) (Finch et al.,
2006; Pelengaris et al., 2002). qPCR and immuno-
blot analyses of pancreatic islets isolated from
pIns-MycERTAM,R26MER/WT, andR26MER/MER mice
indicated that MycERTAM mRNA and protein ex-
pression were 15-fold higher in pIns-MycERTAM
islets than that of MycERT2 in islets from homozygous
R26MER/MER animals (Figure 5A; Figure S5C). To directly com-
pare the net outcome of acute Myc activation in pIns-MycERTAM
versus Rosa26MER/MER islets, we activated MycER in vivo for
3 and 6 days and then stained pancreatic tissue sections for
markers of proliferation (Ki-67) and apoptosis (TUNEL). As
expected (Finch et al., 2006; Pelengaris et al., 2002), high levels
of activated Myc in the pIns-MycERTAM islets induced prolifera-
tion together with both ARF induction and overwhelming b cell
apoptosis, resulting in rapid islet involution. By contrast,
activation of low-level Myc in islets of R26MER/MER mice drove
proliferation without any attendant apoptosis or islet involution,
resulting in progressive islet hyperplasia (Figure 5B; Figure S7).
Likewise, activation of low-level MycERT2 in lung epithelium of
R26MER/MER mice failed to elicit ARF expression, whereas the
high levels of MycERT2 delivered into lung epithelium by adeno-
viral vector potently induced ARF upon tamoxifen activation
(Figure S5D). Hence, in both b cells and lung in vivo, deregulated
Myc is competent to activate intrinsic tumor suppression
pathways so long as it is expressed at elevated levels.
There are two plausible explanations for how different thresh-
old levels of Myc might preferentially trigger proliferation versus
apoptosis. It could be that low and high levels of Myc engage dif-
ferent sets of target genes, perhaps due to differing affinity Myc-
binding promoter/enhancer elements (i.e., Myc discriminates)Cancer Cell 14, 447–457, December 9, 2008 ª2008 Elsevier Inc. 451
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the apoptotic transcriptional program. Alternatively, Myc might
regulate the same genes in each case, but to a greater extent
when expressed at a higher level, and the differential Myc out-
puts arise from different thresholds at which the proliferative
and apoptotic programs fire (i.e., downstream factors decide)
(Figure S8B). In this case, low-level Myc still activates the
apoptotic program, but to a level insufficient to trigger it. We rea-
soned that if the second model holds, subapoptotic low-level
Myc should, by priming the apoptotic machinery, sensitize cells
to induction of apoptosis by other triggers. We therefore ex-
posed R26MER/MER mice to both tamoxifen, to activate MycERT2
in tissues, and a subapoptotic dose of the cytotoxic agent
doxorubicin. The combination of both subapoptotic stimuli trig-
gered significant apoptosis in several tissues, including pancre-
atic islets and liver, and significantly exacerbated the extent of
Myc-induced apoptosis in colonic epithelium (Figures 6A and
6B). Thus, low-level deregulated Myc, although insufficient to
trigger apoptosis itself, nonetheless engages the Myc apoptotic
program.
Deregulation of Low-Level Myc Is Tumorigenic
Although low-level deregulated Myc is sufficient to drive ectopic
proliferation in tissues, it remained possible that actual tumorige-
Figure 5. Induction of Apoptosis Requires Higher Levels of Deregu-
lated Myc than Induction of Ectopic Proliferation
(A) qPCR analysis ofMycERmRNA expression in islets isolated from disaggre-
gated pancreata of untreated designated mice, pooled according to genotype
(n > 2 per cohort). Expression was normalized to GUS, and results are
expressed relative to MycERT2 mRNA in R26MER/MER islets.
(B) TUNEL staining of pancreatic islets from R26MER/MER mice treated with
tamoxifen for 3 (n = 7) or 6 (n = 6) days, with matched samples from similarly
treated pIns-MycERTAM mice (lower panels). Ki-67 staining of adjacent
sections from R26MER/MER pancreata (upper panels) demonstrates tamoxi-
fen-induced functionality of Rosa26-driven MycERT2 protein.452 Cancer Cell 14, 447–457, December 9, 2008 ª2008 Elsevier Incnicity, like apoptosis and ARF induction, requires higher-level
Myc expression. To investigate this, we used intranasal delivery
of recombinant adenovirus-expressing Cre (Ad-Cre) to trigger
sporadic expression ofMycERT2 in lung epithelia of homozygous
R26lsl-MER/lsl-MER mice. MycERT2 was then activated by daily sys-
temic administration of tamoxifen for 3 (n = 4) or 6 (n = 5) weeks.
After 3 weeks of sustained Myc activity, bronchiolar (Figure 7A,
panel 1) and bronchioalveolar junction regions (panel 2) of
R26lsl-MER/lsl-MER lungs exhibited multiple hyperplastic and
dysplastic epithelial foci with pseudostratification and occa-
sional micropapillary tuft formation. After 6 weeks, more exten-
sive micropapillary and papillary hyperplasia was clearly evident
(panel 3), with several bronchioles exhibiting Clara cell hyperpla-
sia and sloughing into the airway lumen (panel 4). These Myc-
induced lesions closely resemble the early bronchioalveolar
lesions that develop 6–8 weeks after sporadic activation of onco-
genic K-RasG12D driven from the endogenous KRas2 promoter
(Jackson et al., 2001, 2005; Johnson et al., 2001).
Individually, Myc or Ras is usually insufficient to drive full tumor
progression, but together they exhibit potent oncogenic cooper-
ation (Land et al., 1983). To ascertain whether low-level deregu-
lated Myc cooperates with Ras oncogenesis in lung epithelium
in vivo, we crossed homozygous R26lsl-MER/lsl-MER and heterozy-
gous R26lsl-MER/WT mice into the conditional LSL-K-RasG12D
model (Jackson et al., 2001, 2005; Johnson et al., 2001). Spo-
radic coexpression of both oncogenes in lung epithelium was
triggered by Ad-Cre inhalation, and MycERT2 was then activated
by tamoxifen administration. Induction of K-RasG12D alone eli-
cited atypical adenomatous hyperplasias within 2 weeks, small
adenomas by 6 weeks postinfection, and overt adenocarcinomas
only after 16–26 weeks (Jackson et al., 2001, 2005). Identical hy-
perplastic and dysplastic bronchiolar lesions arose with identical
kinetics and efficiency in LSL-K-RasG12D;R26lsl-MER/lsl-MER mice
that were not given tamoxifen (i.e., only Ras was activated) (Fig-
ure 7B, panels 1–4) and in control LSL-K-RasG12D-only mice
treated with either oil (n = 2) or tamoxifen (n = 8; data not shown).
By contrast, activation of MycERT2 together with K-RasG12D pro-
foundly accelerated tumor progression compared to K-RasG12D
alone in homozygous, but not heterozygous, Rosa26-lsl-MERT2
animals. By 6 weeks post Ad-Cre infection, papillary adenomas
were both more numerous and significantly larger (panels 5 and 6)
in coactivated mice, some having already progressed to invasive
adenocarcinoma (panels 9–12). Such adenocarcinomas were
poorly differentiated, growing as small tumor clusters with individ-
ual tumor cells embedded within desmoplastic stroma (panel 10).
Whereas few mitotic figures were evident in the lesions induced
by K-RasG12D alone, they were readily detectable in the bronchi-
olar lesions (compare panel 4 and panel 8), adenomas (panel 11),
and adenocarcinomas (panels 11 and 12) induced by K-RasG12D
and MycERT2 together, indicating that low-level expression of de-
regulated Myc confers a significantly higher level of tumor cell
proliferation and is possessed of potent tumorigenic activity.
DISCUSSION
Uncontrolled proliferation of somatic cells is an ever-present risk
for large, long-lived organisms like vertebrates whose tissues
harbor cells that proliferate throughout life. Hence, multiple sur-
veillance mechanisms have evolved to suppress the emergence.
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coupling of tumor suppression to the programs that drive cell
proliferation, a phenomenon dubbed ‘‘intrinsic tumor suppres-
sion’’ (Lowe et al., 2004). Such obligate coupling serves to annul
the immediate growth advantage afforded by oncogenic activa-
tion of the cell’s proliferative machinery. The Myc transcription
factor is a prototypical example of this. In normal cells, Myc
coordinates and drives the diverse intra- and extracellular pro-
grams required for orderly expansion of normal somatic cells.
However, oncogenic Myc triggers the ARF/p53 tumor suppres-
sor pathway and apoptosis, two potent tumor suppressor pro-
grams that efficiently restrain Myc’s oncogenic potential (Evan
and Littlewood, 1998; Lowe et al., 2004). However, for intrinsic
tumor suppression to be compatible with the orderly proliferation
in normal tissues, cells must accurately and reliably discriminate
between normal mitogenic and oncogenic signaling; how they
do this is unclear. One potential distinctive hallmark of oncogenic
signals is their aberrant context: in normal cells, Myc is never
activated alone but always in the context of collateral signaling
pathways. Another possibility is the unusual persistence of
oncogenic Myc—endogenous Myc activity is tightly mitogen de-
pendent and episodic. Finally, as a consequence of its mutation
or its relentless induction by other oncogenes, Myc is usually
present at significantly higher levels in tumors than in normal
cells.
The undeniable importance of intrinsic tumor suppression is
demonstrated by the profound acceleration of oncogenesis in
Myc transgenic mouse models afforded by genetic lesions that
block apoptosis or circumvent the ARF/p53 pathway. Unfortu-
nately, classical transgenic Myc models employ highly active tis-
sue-specific promoter/enhancer elements to drive transgenic
Myc expression in the requisite target tissue. Hence, Myc is
both deregulated and elevated, making it impossible to ascertain
which specific aberrant feature of oncogenic Myc engages tu-
Figure 6. Subapoptotic Myc Synergizes with Suba-
poptotic Doxorubicin to Induce Apoptosis in Multiple
Tissues
(A) TUNEL staining of pancreatic islets (panels 1 and 2), liver
(panels 3 and 4), and colon (panels 5 and 6) from R26WT/WT
(n = 2) and R26MER/MER (n = 4) mice treated for 3 days with
tamoxifen and overnight with 10 mg/kg doxorubicin.
(B) Quantification (mean + SEM) of TUNEL staining in sections
from pancreas (islets), liver, and colon from the mice in (A)
treated with tamoxifen and/or doxorubicin. (n = 2–4 mice per
cohort).
mor suppression. To circumvent this shortcoming,
we made use of the relatively weak, but ubiquitous,
Rosa26 promoter to drive low-level deregulated
expression of the switchable form of Myc,
MycERT2, in target tissues. A MycERT2 open read-
ing frame was inserted downstream of the endog-
enous Rosa26 promoter, but its expression was
blocked by an intervening transcriptional stop ele-
ment flanked by loxP recombination sites. Hit-and-
run excision of the stop element by Cre recombi-
nase triggers targeted expression of MycERT2;
however, MycERT2 activity is dependent upon continuous provi-
sion of 4-OHT ligand.
To ascertain the level at which the Rosa26 promoter drives
MycERT2 expression in adult tissues, we crossed mice harboring
one or two copies of Rosa26-LSL-MycERT2 into the ZP3-Cre
background, which excises the floxed stop element in the egg.
The resultingR26MER animals express MycERT2 from theRosa26
promoter in all tissues. In all R26MER tissues tested, MycERT2
expression levels were broadly comparable, although somewhat
higher in colonic epithelium. In all tissues examined, homozy-
gous R26MER/MER mice expressed approximately twice as much
MycERT2 mRNA and protein as their heterozygous R26MER/WT
littermates.
Acute activation of MycERT2 in tissues of homozygous
R26MER/MER mice triggered widespread ectopic proliferation in
many tissues, including endocrine and exocrine pancreas, liver,
kidney epithelium, lung, skin, and lymphoid organs. In most in-
stances, proliferation was sustained to at least 6 days of contin-
uous Myc activation: analysis beyond this time was curtailed by
precipitous onset of anemia and dehydration that coincided with
intestinal hemorrhage and necessitated euthanasia. In contrast
to homozygous R26MER/MER mice, activation of MycERT2 in het-
erozygous R26MER/WT animals elicited no increased proliferation
in any tissues except colon and, weakly, spleen red pulp. Given
that there is only a 2-fold difference in MycERT2 levels in
heterozygous versus homozygous R26MER mice, this defines
a sharp minimum threshold level of intracellular Myc required
to elicit ectopic proliferation in vivo. It also indicates that the level
of ectopic activated MycERT2 in homozygous R26MER/MER
tissues is close to the minimum necessary to drive ectopic
proliferation. It is interesting that the level of ectopic MycERT2
in heterozygous R26MER/WT tissues, while comparable to that
of endogenous Myc in MEFs proliferating in response to serum,
is insufficient to drive those tissues into the cell cycle. WeCancer Cell 14, 447–457, December 9, 2008 ª2008 Elsevier Inc. 453
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In Vivo
(A) Representative images of hematoxylin and eosin (H&E)-
stained lungs from tamoxifen-treated, Ad-Cre-infected
R26lsl-MER/lsl-MER mice showing multiple preneoplastic pulmo-
nary lesions. Panels 1 and 2: localized epithelial dysplasia (ed)
evident in airway epithelium (panel 1) and bronchioalveolar
junctions (panel 2) after 3 weeks of sustained MycERT2 activa-
tion. Compare with normal bronchiolar epithelium (n). Scale
bars = 20 mm. Panels 3 and 4: micropapillary and papillary
Clara cell hyperplasia present after 6 weeks of sustained
MycERT2 activation. Scale bars = 40 mm.
(B) H&E-stained lungs from Ad-Cre-infected LSL-K-
RasG12D;R26lsl-MER/lsl-MER mice treated with oil carrier (n = 3,
panels 1–4) or tamoxifen (n = 6, panels 5–12) for 6 weeks.
Panels 1, 2, 5, and 6: size comparison between tumors driven
by K-RasG12D alone (1 and 2) and K-RasG12D/MycERT2 com-
bined (5 and 6). Scale bars = 0.4 mm in panels 1 and 5 and
100 mm in panels 2 and 6. The numbered rectangular regions
within panels 1, 3, 5–7, and 9 are shown enlarged in panels 2,
4, 6, 11, 8, and 10, respectively. Panels 3, 4, 7, and 8: micro-
papillary bronchiolar hyperplasia and dysplasia driven by
K-RasG12D alone (3 and 4) and K-RasG12D/MycERT2 combined
(7 and 8). Arrowhead in panel 8 points to a mitotic figure. Scale
bars = 50 mm in panels 3 and 7 and 20 mm in panels 4 and 8.
Panels 9–12: progression to carcinoma observed after 6
weeks of combined KrasG12D/MycERT2-driven oncogenesis.
Scale bars = 100 mm in panel 9 and 20 mm in panels 10–12. Panel 10: nests of solid tumor (st) and isolated tumor cells surrounded by desmoplastic stroma
(ds). Panels 11 and 12: mitotic figures (arrowheads) present in combined K-RasG12D/MycERT2-driven papillary adenoma (pa) and adenocarcinoma (ac).presume that this reflects the fact that serum mitogens engage
both Myc and multiple, additional synergistic signaling path-
ways. By contrast, Myc is the sole engine of proliferation in
R26MER/WT cells. It is also possible that activated MycERT2 has
reduced specific activity compared to wild-type Myc protein,
leading to an overestimation of the level of functional Myc in
R26MER tissues. Of note, while MycERT2 was expressed in all
R26MER/MER tissues tested, some failed to proliferate when
MycERT2 was activated. Why this should be is unclear, but it is
likely that some cell types are constitutionally unable to prolifer-
ate due to structural constraints or lack of critical components
of the cell-cycle machinery. Other cell types may be competent
to proliferate only in response to higher levels of Myc than are
expressed in R26MER/MER tissues. An obvious example of this
would be the many differentiated cell types that express appre-
ciable levels of Mad proteins (Chin et al., 1995; Queva et al.,
1998; Vastrik et al., 1995), which mitigate Myc action by compet-
ing with Myc for Max.
Not only is low-level constitutive expression of MycERT2 suffi-
cient to induce and maintain aberrant proliferation in many nor-
mal R26MER/MER tissues in vivo, it is also oncogenic, efficiently
driving early-stage tumorigenesis in lung epithelium and, in co-
operation with activated Ras, full progression to invasive adeno-
carcinoma (Figure 7). Nonetheless, even though Rosa26-driven
Myc is oncogenic and both deregulated and active out of normal
mitogenic context, it fails to induce either apoptosis or measur-
ableARF expression in most tissue types. This indicates a funda-
mental difference in how Myc engages its oncogenic and tumor-
suppressive outputs. The one notable exception to this is colonic
epithelium, and since this is the R26MER tissue with the highest
level of MycERT2 expression, we hypothesized that overexpres-
sion of Myc is likely the determining trigger of intrinsic tumor sup-454 Cancer Cell 14, 447–457, December 9, 2008 ª2008 Elsevier Incpression. We confirmed this directly in pancreatic b cells and
lung epithelium: in both tissues, further elevation of Myc levels
triggered both apoptosis and ARF. Therefore, we conclude
that it is the aberrant intensity of oncogenic Myc, and not its ab-
normal persistence or context, that triggers intrinsic tumor sup-
pression. Recently, it was shown that induction of both ARF and
replicative senescence by activated Ras in vivo also requires
overexpression of the activated oncoprotein (Sarkisian et al.,
2007). Hence, preternaturally high intensity appears to be the
general metric by which cells discriminate between normal and
oncogenic signals. However, we do not discount the possibility
that even low levels of deregulated Myc may be sufficient in
some cell lineages to engage apoptosis and/or ARF expression
at some level that suppresses tumor initiation. Indeed, data from
studies on transgenic Myc in the well-characterized Em-myc
lymphoma model suggest that even very low Myc levels can,
at some point in tumor evolution, contribute to the selective pres-
sure to inactivate ARF or p53 (Bertwistle and Sherr, 2007).
Paradoxically, our data suggest that low-level deregulated
Myc may be a more efficient initiator of oncogenesis than Myc
that is overexpressed, since the latter can be tolerated only by
cells that have already lost their tumor suppressor pathways. In-
deed, high initial levels of Myc may even impede onset of tumor-
igenesis, a conclusion consistent with surprising recent findings
that coexpression of Myc delays the mean latency of tumor on-
set in a transgenicRasG12D lung tumor model (Tran et al., 2008).
This elegant study used theCC10 promoter to drive doxycycline-
dependent Myc expression in Clara cells and alveolar type II
pneumocytes at very high levels, at least ten times the quasiphy-
siological level of MycERT2 in lung epithelium of R26MER/MER
mice (Figure 2A). As our data show, such high levels of Myc
breach the ARF/apoptotic triggering threshold, and by engaging.
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staunching tumorigenesis. By contrast, oncogenic cooperation
in the LSL-K-RasG12D;R26lsl-MER/lsl-MER mouse is efficient
because it involves levels of oncogenic Myc (and presumably
Ras) that are too low to trigger significant intrinsic tumor
suppression. We surmise that low-level oncogene expression
may be a general characteristic of early-stage spontaneous
tumors and that most tumors evolve via a two-stage selective
process. Early on, when tumor suppressor pathways remain
intact, selection strongly favors low-level oncogene activity
and the relatively indolent clonal expansion it confers. Elevated
oncogene activity, together with the increased aggressiveness
it confers on tumors, becomes subject to positive selection
only once the appropriate intrinsic tumor suppressor pathways
have been eroded by sporadic mutation.
How might different levels of Myc trigger such distinct biolog-
ical outputs? One possibility is that Myc-induced ARF/p53 and
apoptosis are mediated by a distinct set of target genes, perhaps
those with lower-affinity promoter/enhancer elements that re-
spond only to elevated Myc levels (Figure S5A). Alternatively,
Myc might regulate identical sets of gene targets in both cases,
although to lesser or greater overall extents when Myc is low or
high, respectively, with net outcome determined by the different
execution thresholds of each output program (Figure S5B). To
distinguish between the two possibilities, we asked whether ex-
pression of Myc at levels that trigger no overt apoptosis nonethe-
less reduces the threshold for induction of apoptosis by other
insults. MycERT2 was globally activated in R26MER/MER mice,
which were then systemically exposed to the cytotoxic drug
doxorubicin at a dose that was itself subapoptotic. The combina-
tion of sublethal Myc and doxorubicin induced apoptosis in sev-
eral tissues. Myc-induced apoptosis is mediated through the in-
trinsic mitochondrial pathway (Juin et al., 1999) that is triggered
when the antiapoptotic buffering of the Bcl-2/Bcl-xL proteins is
neutralized by the sum of activated BH3 proteins. Our data imply
that low-level Myc still activates its requisite BH3 apoptotic ef-
fectors, but to a level insufficient to neutralize Bcl-2/Bcl-xL with-
out the cooperation of collateral apoptotic signals. Of note, we
saw no correlation between Myc-induced proliferation and
Myc-induced sensitivity to doxorubicin in different tissues, indi-
cating that Myc-dependent doxorubicin sensitivity is not merely
a consequence of these tissues’ increased proliferative status
but reflects an inherent variability in the innate sensitivity to
Myc-induced apoptosis among different cell types in vivo.
Indeed, even in any one cell type, the threshold for triggering
Myc-induced apoptosis is highly dependent upon changes in rel-
ative levels of the Bcl-2-family proteins (Bissonnette et al., 1992;
Fanidi et al., 1992; Juin et al., 2002; Wagner et al., 1993) and
availability of survival signals (Harrington et al., 1994a, 1994b).
Hence, the level of Myc required to trigger apoptosis is not an in-
nate, fixed property of a cell but is exquisitely dependent upon
the cell’s internal state and microenvironment. Importantly,
such tissue-specific variations in the threshold set points for
Myc oncogenic and apoptotic output mean that the innate
susceptibilities of different tissues to Myc-driven oncogenesis
will depend greatly on the level at which oncogenic Myc is
expressed. Whether the operational threshold at which Myc trig-
gers ARF is similarly subject to such protean, cell-type-specific
influences is unknown. One final implication of the different firingCthresholds at which Myc’s distinct outputs (proliferation and
tumor suppression) are set is that relatively subtle changes in
overall Myc activity may suffice to shift above or below each
specific threshold, thereby triggering dramatically different out-
comes. Likewise, it is possible that mutations that merely aug-
ment or degrade overall Myc activity, by shifting the effective
level of Myc above or below different output thresholds, could
appear selective for specific Myc functions.
EXPERIMENTAL PROCEDURES
Generation of Rosa26-MER Targeting Vector and Mice
c-myc cDNA lacking a stop codon was excised from pBabe-MycERTAM (Little-
wood et al., 1995) and annealed to T2 point-mutated ligand-binding domain of
human estrogen receptor from pCreERT2 (Indra et al., 1999), followed by the
IRES-EGFP fragment (generously provided by D. Dankort and M. McMahon,
UCSF), generating c-MycERT2-IRES-EGFP (MIE). This MIE fragment was
then incorporated into the previously described Rosa26 vector pBigT (Srinivas
et al., 2001) and excised, incorporating both the floxed stop/neomycinR cas-
sette and MIE. The final vector, pRosa26fsMIE, was linearized with SwaI and
transfected into murine embryonic stem cells, and neomycin-resistant clones
were identified by Southern blotting. An internal probe was generated by ran-
dom priming from a gel-purified 1.6 kb NcoI/HindIII fragment of pR26-PAS,
further digested with AscI to separate it from comigrating DNA. An external
probe was generated by random priming from a 330 bp NotI fragment of the
Rosa26 promoter, generously provided by P. Soriano (Fred Hutchinson
Cancer Research Center, Seattle). Chimeric mice were initially bred with
C57BL/6 mice until germline transmission of the allele was observed. The con-
sequent R26-lsl-MycERT2 mouse line was bred to C57BL/6, then alternately to
FVBN, and maintained on a mixed FVBN/C57BL/6 background.
Other Mouse Strains, Procedures, and Genotyping
All procedures involving mice were performed in accordance with protocol
number AN 076148 (UCSF Institutional Animal Care and Use Committee).
Zp3-Cre (Lewandoski et al., 1997), LSL-K-RasG12D (Jackson et al., 2001),
p19ARF/ (Kamijo et al., 1999), and pIns-MycERTAM (Pelengaris et al., 2002)
mice have been described previously. Tamoxifen (Sigma), dissolved in peanut
oil, was administered daily by intraperitoneal (i.p.) injection for a maximum of
6 weeks at a dose of 1 mg/20 g body mass per day. For BrdU/IdU double
labeling, bromodeoxyuridine (Sigma) and iododeoxyuridine (Sigma) dissolved
in Tris-buffered saline were injected i.p. three times at 6 hr intervals on day 3,
while IdU was injected one time 5–6 hr prior to harvest 1 day after the last ta-
moxifen injection (day 6). To deliver adenovirus-Cre recombinase (Ad-Cre),
mice were anesthetized with 2.5% Avertin (250 ml/20 g body mass) and 5 3
107 plaque-forming units of Ad-Cre were administered as described previously
(Fasbender et al., 1998). Details of primer/probe sets used for genotyping and
expression analysis can be found in the Supplemental Data.
Cell Culture and Immunoblotting
Embryonic fibroblasts were isolated from E13.5 R26-lsl-MycERT2 and R26-
MycERT2 mice. Whole-cell lysates were prepared by dissolving cells in Tween
lysis buffer (150 mM NaCl, 50 mM HEPES [pH 7.5], 1 mM EDTA, 2.5 mM EGTA,
0.1% Tween 20 plus Complete protease inhibitor cocktail [PIs; Roche])
followed by sonication. Nuclear extracts were prepared in low-salt buffer
(20 mM KCl, 10 mM HEPES [pH 7.5], 1 mM MgCl2, 1 mM CaCl2, 0.1% Triton
X-100 plus PIs). For liver extracts, freshly isolated livers were homogenized
in 103 volume/weight T-Per (Pierce) + PIs and fractionated by centrifugation
at 1,000 3 g, and the pellets were resuspended in 1 volume T-Per + 0.2%
SDS, followed by sonication. Islets were prepared from disaggregated pan-
creata as described previously (Lawlor et al., 2006) and lysed in Tween lysis
buffer, sonicated, and cleared by centrifugation at 12,0003 g prior to loading.
For p19ARF analysis, cell lysates were loaded on glycerol/acrylamide gels, frac-
tionated by discontinuous electrophoresis, and electroblotted onto PVDF
membranes. Anti-ERa (Santa Cruz, SC-543), anti-c-Myc (Santa Cruz, SC42
and 9E10), X-Myc1 (G.I.E.), and anti-p19ARF 5-C3-1 (Bertwistle et al., 2004)
were generously provided by M. Roussel (St. Jude Children’s Researchancer Cell 14, 447–457, December 9, 2008 ª2008 Elsevier Inc. 455
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Thresholds Govern the Biological Output of MycHospital, Memphis, TN, USA); anti-lamin A/C (Santa Cruz, SC7293) and
anti-a-actin (Sigma) were used as primary antibodies. Secondary horse-
radish peroxidase-conjugated antibodies (Amersham) were detected by
chemiluminescence.
Immunohistochemistry and Immunofluorescence
Paraffin-embedded sections (5 mm thick) were probed with Ki-67 antibody
(NeoMarkers, SP6) used at 1:200 in 3% BSA overnight at 4C and detected
with biotinylated goat anti-rabbit (Vector Labs) followed by Vectastain ABC
detection (Vector Labs) using stable diaminobenzidine (DAB) solution (Invitro-
gen). For BrdU/IdU double staining, mouse a-BrdU (1:20, Roche), which
recognizes both BrdU and IdU, was used in conjunction with rat a-BrdU
(1:200, Serotec), which recognizes BrdU only. Bound primary antibodies
were detected using Alexa 488-conjugated a-mouse IgG and Alexa 568-con-
jugated a-rat IgG (Molecular Probes). For p19ARF immunohistochemistry,
blocking was performed in 10% normal goat serum (NGS) with 0.1% Triton
X-100. Primary antibody (5-C3-1) was diluted 1:10 in 3% NGS + 0.1% Triton
X-100 and incubated overnight at 4C. TUNEL staining was performed using
an ApopTag peroxidase labeling kit (Chemicon) or an ApopTag fluorescein
labeling kit (Chemicon) according to the manufacturer’s directions. Otherwise,
tissue sections were blocked overnight in 3% BSA prior to addition of
peroxidase-conjugated anti-digoxigenin.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, eight
figures, and one table and can be found with this article online at http://www.
cancercell.org/supplemental/S1535-6108(08)00367-X.
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